Erasca narrows ERAS-0015 Phase 1 data readout timeline to mid-May 2026

Erasca, Inc.

Narrowed Phase 1 monotherapy data readout for pan-RAS molecular glue ERAS-0015 to no later than mid-May 2026 (prior: first half 2026).
Data from two trials: Erasca's AURORAS-1 (RAS-mutant solid tumors) and Joyo's JYP0015M101 (China, specific RAS mutations).
No financial or regulatory update; no safety or efficacy data disclosed yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.